<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03867929</url>
  </required_header>
  <id_info>
    <org_study_id>2</org_study_id>
    <nct_id>NCT03867929</nct_id>
  </id_info>
  <brief_title>Serum Levels of 25-Hydroxy Vitamin D in Patients With Moderate and Severe Erectile Dysfunction</brief_title>
  <official_title>Serum Levels of 25-Hydroxy Vitamin D in Patients With Moderate and Severe Erectile Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Recep Tayyip Erdogan University Training and Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Recep Tayyip Erdogan University Training and Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In present study, we aimed to investigate the association between erectile function severity&#xD;
      of serum 25-Hydroxyvitamin-D and cut-off level to treat men with erectile dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators retrospectively analysed 130 patients admitted to the complaint of erectile&#xD;
      dysfunction between aged between 18-80 years old from June 2017 to October 2018 at Cigli&#xD;
      Region Training Hospital Urology department and Recep Tayyip Erdogan University Urology&#xD;
      Department. International index of erectile function-5 (IIEF-5) Turkish validated short form&#xD;
      quesstionaire was performed to all patients. Antropometric characteristics including weight,&#xD;
      height, waist circumference, body mass index (BMI) and presence of comorbide diseases were&#xD;
      recorded. After detailed history and physical examination performed all patients, overnight&#xD;
      fasting in the morning between 08:00-10:00, blood samples from antecubital vein were&#xD;
      performed and serum glucose, lipid profile, follicular stimulating hormon (FSH), Luteinizing&#xD;
      hormone (LH), total testosterone, prolactin, estradiol, 25(OH)D level were analysed. Presence&#xD;
      of uncontrolled diabetes mellitus, uncontrolled hypertension, uncontrolled lipid metabolism&#xD;
      disorders, neurological diseases, heamatological diseases, urinary tract infection,&#xD;
      malignencies, chronic kidney failure, metabolic syndrome, psychiatric diseases and/or medical&#xD;
      treatment, smoking, history of pelvic surgery, cardiac surgery and pelvic radiotherapy were&#xD;
      accepted as exclusion criterias from the study. After IIEF-5 score adjust as 21 point, ROC&#xD;
      analyse was used to calculate the cut-off value of 25(OH)D and level of 27.32 ng/mL was&#xD;
      calculated as cut-off value. Patients were divided into two group according to 27.32 ng/mL&#xD;
      level as a cut off value. Serum 25(OH)D level was lower than 27.32 ng/mL in group 1 (severe&#xD;
      and moderate symptomatic group) and higher than 27.32 ng/mL in group 2 (mild symptomatic&#xD;
      group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Actual">September 1, 2020</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <target_duration>15 Months</target_duration>
  <primary_outcome>
    <measure>Laboratory results</measure>
    <time_frame>1 year</time_frame>
    <description>Serum 25 Hydroxy vitamin D levels (ng/mL), group 1 include patients with serum 25 hydroxy vitamin D levels higher than 27.32 ng/ml and Group 2 include patients with serum 25 hydroxy vitamin D levels lower than 27.32 ng/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical results</measure>
    <time_frame>1 year</time_frame>
    <description>IIEF-5 quesstionaire score (0-15 point is severe erectile dysfunction, 16-21 point is moderate erectile dysfunction and &gt;21 point is mild erectile dysfunction)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">130</enrollment>
  <condition>Erectile Dysfunction</condition>
  <arm_group>
    <arm_group_label>STUDY</arm_group_label>
    <description>Patient with serum 25-Hydroxy vitamin D level &lt;27.32</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <description>Patient with serum 25-Hydroxy vitamin D level &gt;27.32</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>25-Hydroxy vitamin D</intervention_name>
    <description>27.32 is calculated as a cut fo level for 25 hydroxy vitamin D deficiency</description>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_label>STUDY</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with erectile dysfunction aged between 18 and 80 years&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presence of erectile dysfunction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of uncontrolled diabetes mellitus,&#xD;
&#xD;
          -  Presence of uncontrolled hypertension,&#xD;
&#xD;
          -  Presence of uncontrolled lipid metabolism disorders,&#xD;
&#xD;
          -  Presence of neurological diseases,&#xD;
&#xD;
          -  Presence of heamatological diseases,&#xD;
&#xD;
          -  Urinary tract infection,&#xD;
&#xD;
          -  Diagnosis of any malignencies,&#xD;
&#xD;
          -  Chronic kidney failure,&#xD;
&#xD;
          -  Presence of metabolic syndrome,&#xD;
&#xD;
          -  Presence of psychiatric diseases and/or medical treatment,&#xD;
&#xD;
          -  Smoking,&#xD;
&#xD;
          -  History of pelvic surgery, cardiac surgery and pelvic radiotherapy&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>erectile dysfunction</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Mustafa Ozan Horsanalı, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cigli Regional Training Hospital, Urology Department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cigli Regional Training Hospital</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>March 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2019</study_first_posted>
  <last_update_submitted>October 6, 2020</last_update_submitted>
  <last_update_submitted_qc>October 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Recep Tayyip Erdogan University Training and Research Hospital</investigator_affiliation>
    <investigator_full_name>Mustafa Ozan HORSANALI</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>Erectile dysfunction</keyword>
  <keyword>Vitamin-D</keyword>
  <keyword>Hypogonadism</keyword>
  <keyword>Endothelial Dysfunction</keyword>
  <keyword>Nitric Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erectile Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Hydroxycholecalciferols</mesh_term>
    <mesh_term>Calcifediol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

